Gan & Lee Pharmaceuticals' Insulin Glargine Injection Receives UK Marketing Approval

On October 11, according to Gan & Lee Pharmaceuticals, the company's independently developed and produced insulin glargine injection has officially received marketing authorization from the UK Medicines and Healthcare products Regulatory Agency for the treatment of diabetes in adults, adolescents, and children aged 2 years and older.